Page 788 - Read Online

Page 14 of 14 Stolz et al. Mini-invasive Surg 2020;4:76 I http://dx.doi.org/10.20517/2574-1225.2020.69

their mechanisms and therapeutic implications. JACC Cardiovasc Imaging 2020;13:820-35.
67. Tigges E, Blankenberg S, von Bardeleben RS, et al. Implication of pulmonary hypertension in patients undergoing MitraClip therapy:
results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 2018;20:585-94.
68. Yucel E, Al-Bawardy R, Bertrand PB. Pulmonary hypertension in patients eligible for transcatheter mitral valve repair: prognostic impact
and clinical implications. Curr Treat Options Cardiovasc Med 2019;21:60.
69. Al-Bawardy R, Vemulapalli S, Thourani VH, et al. Association of pulmonary hypertension with clinical outcomes of transcatheter mitral
valve repair. JAMA Cardiol 2020;5:47-56.
70. Osteresch R, Diehl K, Kühl M, et al. Impact of right heart function on outcome in patients with functional mitral regurgitation and chronic
heart failure undergoing percutaneous edge-to-edge-repair. J Interv Cardiol 2018;31:916-24.
71. Kaneko H, Neuss M, Weissenborn J, Butter C. Prognostic significance of right ventricular dysfunction in patients with functional mitral
regurgitation undergoing MitraClip. Am J Cardiol 2016;118:1717-22.
72. Giannini C, Fiorelli F, Colombo A, et al. Right ventricular evaluation to improve survival outcome in patients with severe functional
mitral regurgitation and advanced heart failure undergoing MitraClip therapy. Int J Cardiol 2016;223:574-80.
73. Godino C, Salerno A, Cera M, et al. Impact and evolution of right ventricular dysfunction after successful MitraClip implantation in
patients with functional mitral regurgitation. Int J Cardiol Heart Vasc 2016;11:90-8.
74. Schueler R, Öztürk C, Sinning JM, et al. Impact of baseline tricuspid regurgitation on long-term clinical outcomes and survival after
interventional edge-to-edge repair for mitral regurgitation. Clin Res Cardiol 2017;106:350-8.
75. Al-Hindwan HSA, Silbernagel G, Curio J, et al. The impact of moderate aortic valve disease in patients undergoing MitraClip for severe
MR. Clin Hemorheol Microcirc 2020; doi: 10.3233/CH-200818.
76. Geis NA, Puls M, Lubos E, et al. Safety and efficacy of MitraClip™ therapy in patients with severely impaired left ventricular ejection
fraction: results from the German transcatheter mitral valve interventions (TRAMI) registry. Eur J Heart Fail 2018;20:598-608.
77. Gyoten T, Messroghli D, Schenk S, et al. Impact of preinterventional tricuspid regurgitation on outcome of MitraClip therapy in patients
with severely reduced ejection fraction. Open Heart 2020;7:e001203.
78. Asch FM, Grayburn PA, Siegel RJ, et al; COAPT Investigators. Echocardiographic outcomes after transcatheter leaflet approximation in
patients with secondary mitral regurgitation: the COAPT trial. J Am Coll Cardiol 2019;74:2969-79.
79. Schueler R, Nickenig G, May AE, et al. Predictors for short-term outcomes of patients undergoing transcatheter mitral valve interventions:
analysis of 778 prospective patients from the German TRAMI registry focusing on baseline renal function. EuroIntervention 2016;12:508-
14.
80. Triantafyllis AS, Kortlandt F, Bakker AL, et al. Long-term survival and preprocedural predictors of mortality in high surgical risk patients
undergoing percutaneous mitral valve repair. Catheter Cardiovasc Interv 2016;87:467-75.
81. Kyhse-Andersen J, Schmidt C, Nordin G, et al. Serum cystatin C, determined by a rapid, automated particle-enhanced turbidimetric
method, is a better marker than serum creatinine for glomerular filtration rate. Clin Chem 1994;40:1921-6.
82. Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. Biomark Med
2010;4:265-80.
83. Sims JR, Reeder GS, Guerrero M, et al. Characteristics and outcomes of patients with normal left atrial pressure undergoing transcatheter
mitral valve repair. Heart 2020;106:898-903.
84. Gotzmann M, Sprenger I, Ewers A, Mügge A, Bösche L. One-year outcome of percutaneous mitral valve repair in patients with severe
symptomatic mitral valve regurgitation. World J Cardiol 2017;9:39-46.
85. Buccheri S, Capodanno D, Barbanti M, et al. A risk model for prediction of 1-year mortality in patients undergoing MitraClip
implantation. Am J Cardiol 2017;119:1443-9.
86. Ailawadi G, Lim DS, Mack MJ, et al. One-year outcomes after MitraClip for functional mitral regurgitation. Circulation 2019;139:37-47.
87. Kalbacher D, Schäfer U, von Bardeleben RS, et al. Impact of tricuspid valve regurgitation in surgical high-risk patients undergoing
MitraClip implantation: results from the TRAMI registry. EuroIntervention 2017;12:e1809-16.
88. Matsumoto T, Nakamura M, Yeow WL, et al. Impact of pulmonary hypertension on outcomes in patients with functional mitral
regurgitation undergoing percutaneous edge-to-edge repair. Am J Cardiol 2014;114:1735-9.
89. Dörr O, Walther C, Liebetrau C, et al. Evaluation of cystatin C and neutrophil gelatinase-associated lipocalin as predictors of mortality in
patients undergoing percutaneous mitral valve repair (MitraClip). Clin Cardiol 2018;41:1474-9.
90. Keßler M, Seeger J, Muche R, et al. Predictors of rehospitalization after percutaneous edge-to-edge mitral valve repair by MitraClip
implantation. Eur J Heart Fail 2019;21:182-92.